Safety concerns for Acadia's Nuplazid resurface

On April 9, CNN called out a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among 2,236 adverse event reports filed for patients taking Nuplazid pimavanserin from Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) to treat Parkinson's disease psychosis (PDP).

ISMP composes its reports using data from the FDA Adverse Event Reporting System (FAERS), a publicly available database created to collect adverse event data after a drug goes to market (see BioCentury Innovations, Oct. 5, 2017)...